Gastrointestinal stromal tumor

The targeted drug Qinlock, which interferes with the activity of proteins that drive gastrointestinal stromal tumor, has been approved by the Food and Drug Administration for patients with advanced disease that has progressed despite treatment with other kinase inhibitors.
 

Patients with gastrointestinal stromal tumors have a new targeted therapy that looks to tackle secondary mutations after it showed a strong response rate in the clinic.
 

The Food and Drug Administration approved Ayvakit for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor who exhibited a platelet-derived growth factor receptor alpha exon 18 mutation.
 

How zeroing in on the mutation in gastrointestinal stromal tumors is adding years to patients’ lives

The Life Raft Group, a patient advocacy organization, is teaming up with research organizations to hopefully find the next wave of treatment for patients with gastrointestinal stromal tumors.

Identified only a decade-and-a-half ago, GIST is already treatable with several targeted therapies, and scientists are researching more.

Melissa D. Shepherd, an acute care nurse practitioner from the Huntsman Cancer Institute in Salt Lake City, Utah, discusses side effects associated with second- and third-line treatments for GIST.

Melissa Shepherd, an acute care nurse practitioner from the Huntsman Cancer Institute in Salt Lake City, Utah, discusses side effects associated with treatment for gastrointestinal stromal tumors (GIST).

Melissa D. Shepherd, Acute Care Nurse Practitioner, Huntsman Cancer Institute, discusses the various players involved in the care of a patient with GIST (gastrointestinal stromal tumors).

Melissa D. Shepherd, describes what gastrointestinal stromal tumors (GIST) are — tumors that arise in the esophagus, stomach, small bowel, large bowel or the rectum.